At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed esophageal cancer
- ✓Stage IV disease based on 8th AJCC TNM classification or recurrent esophageal cancer
- ✓Planned treatment with anti-PD-1/PD-L1 immunotherapy
- ✓Age ≥18 years
- ✕Esophageal perforation or hematemesis
- ✕Active autoimmune disease or history of autoimmune disease requiring immunosuppressive agents or systemic hormonal therapy within 28 days
- ✕Disease progression within 3 months after anti-PD-1/PD-L1 immunotherapy
- ✕Allergy to macromolecular protein preparations or anti-PD-1/PD-L1 inhibitor components
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Precision Palliative Care for Patients With Advanced Esophageal Cancer: a Randomized Phase III Trial
In Brief
An observational study evaluating precision palliative care for Esophageal Cancer. Currently recruiting, targeting 624 participants across 1 site.
Detailed Summary
The goal of this clinical trial is to learn if precision palliative care improves survival of patients with advanced esophageal cancer in adults. Researchers will compare precision palliative care and standard palliative care to see if precision palliative care works more effectively to treat advanced esophageal s cancer. Participants will receive precision palliative care or standard palliative care. All participants will answer survey questions about their quality of life, MDASI, PHQ-9, GAD-7 for 1 years.
Study Details
Timeline
Interventions
Participants receive precision palliative care based on scale screening result.